BOTTA, CIRINO
 Distribuzione geografica
Continente #
NA - Nord America 293
AS - Asia 156
EU - Europa 155
SA - Sud America 21
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 632
Nazione #
US - Stati Uniti d'America 282
SG - Singapore 134
IT - Italia 89
BR - Brasile 17
GB - Regno Unito 17
SE - Svezia 12
DE - Germania 10
CA - Canada 7
CN - Cina 7
FI - Finlandia 7
HK - Hong Kong 7
NL - Olanda 7
ES - Italia 4
EU - Europa 4
PL - Polonia 4
BD - Bangladesh 3
CL - Cile 3
CZ - Repubblica Ceca 3
IN - India 3
MX - Messico 3
NZ - Nuova Zelanda 2
AU - Australia 1
BB - Barbados 1
BY - Bielorussia 1
EC - Ecuador 1
PK - Pakistan 1
PT - Portogallo 1
VN - Vietnam 1
Totale 632
Città #
Singapore 95
Chandler 47
Santa Clara 24
Milan 16
London 15
Chicago 14
Princeton 13
Lawrence 12
Ashburn 11
Munich 9
Catanzaro 8
Hong Kong 7
Ottawa 6
Boardman 5
Turku 5
Wilmington 5
Des Moines 4
Lamezia Terme 4
Redmond 4
São Paulo 4
Utrecht 4
Barcelona 3
Castrovillari 3
Mexico City 3
Naples 3
Phoenix 3
Redwood City 3
Rome 3
Rosarno 3
San Antonio 3
San Nicola Manfredi 3
The Dalles 3
Chennai 2
Cortale 2
Grottaglie 2
Helsinki 2
Leawood 2
New York 2
Olomouc 2
Padova 2
Palermo 2
San Francisco 2
Santiago 2
Santo Stefano di Rogliano 2
Seattle 2
Warsaw 2
Acri 1
Alagoinhas 1
Amargosa 1
Auckland 1
Bari 1
Birmingham 1
Bridgetown 1
Brooklyn 1
Catania 1
Clarksburg 1
Clearwater 1
Crotone 1
Dallas 1
Denver 1
Dhaka 1
Filadelfia 1
Guangzhou 1
Hanover 1
Iapu 1
Ipiaú 1
Irving 1
Kansas City 1
Kensington 1
Lahore 1
Los Angeles 1
Mascalucia 1
Mineiros 1
Minsk 1
Norwalk 1
Ocala 1
Oristano 1
Ovada 1
Parma 1
Pelotas 1
Rende 1
Rio Claro 1
Riverview 1
Roccella Jonica 1
Saint Louis 1
Salvador 1
Santo Estêvão 1
Santos 1
Saquisilí 1
Settingiano 1
Shamokin 1
Shanghai 1
Smithfield 1
Sydney 1
São Gonçalo 1
São João do Rio do Peixe 1
Tallahassee 1
Thủ Đức 1
Toronto 1
Trieste 1
Totale 427
Nome #
miR-22 suppresses DNA ligase III addiction in multiple myeloma 84
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 53
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells. 48
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 45
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 44
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 36
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 36
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 35
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 34
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 32
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility 31
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response 30
Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma 28
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 28
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 22
Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report 21
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 20
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 18
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 17
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies 16
Totale 678
Categoria #
all - tutte 7.762
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.762


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202149 4 0 3 2 1 7 2 5 12 10 3 0
2021/202267 0 0 1 11 7 2 7 9 8 9 13 0
2022/2023151 25 16 16 5 12 14 6 7 26 7 13 4
2023/2024104 24 13 5 18 9 19 0 0 3 2 2 9
2024/2025294 29 7 10 19 21 42 13 13 29 4 41 66
2025/20261 1 0 0 0 0 0 0 0 0 0 0 0
Totale 678